Focus: Alzamend Neuro is a public biotechnology company focused on Alzheimer's disease treatment, headquartered in Atlanta with a pipeline of early-stage candidates.
Profile data last refreshed 20h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Alzamend Neuro to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Alzamend Neuro
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Alzamend Neuro's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
April 2026 in Review: Updates on the Psychiatric Treatment Pipeline - Psychiatric Times
April 2026 in Review: Updates on the Psychiatric Treatment Pipeline Psychiatric Times
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Alzamend Neuro (ALZN) and Cardiol Therapeutics (CRDL) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Alzamend Neuro (ALZN) and Cardiol Therapeutics (CRDL) The Globe and Mail
FINRA Says Compliance Chief Took Part In Pre-IPO Fraud - Law360
FINRA Says Compliance Chief Took Part In Pre-IPO Fraud Law360
8-K Filing: Alzamend Neuro, Inc. (ALZN) (CIK 0001677077)
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo